Your AI-Trained Oncology Knowledge Connection!
We sat down with Ajai Chari, MD, and Sundar Jagannath, MD, both of Mount Sinai Hospital, to provide insight on controversial, but critical, questions regarding the merits of quadruplet versus triplet therapy in the newly diagnosed setting, the optimal maintenance approach in high-risk patients, and the data in support of and against initiating treatment in patients with smoldering multiple myeloma.
We traveled to Salt Lake City, Utah, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from the University of Utah and Intermountain Healthcare.
Howard A. Burris, MD, also known as "Skip," of Sarah Cannon Research Institute, discussed how he wound up in the oncology space, his passion for getting to know and helping his patients, and some proud moments throughout his monumental career.
We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the University of Pittsburgh Medical Center faculty.
In keeping up with the expanding breast cancer treatment armamentarium, we sat down with Jane L. Meisel, MD, and Aditya Bardia, MD, MPH, who shed light on emerging treatment strategies for patients with metastatic triple-negative breast cancer and discussed the optimal timing of genomic testing in women with progressive hormone receptor–positive disease.
We traveled to Seattle, Washington, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Seattle Cancer Care Alliance faculty.
We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer, which featured insights from key thought leaders at Carbone Cancer Center of the University of Wisconsin.
We traveled to Pasadena, California, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from City of Hope faculty.
Maha Hussain, MD, FACP, FASCO, reflects on the path that led her into genitourinary cancers, and the challenges she has overcome in her career while offering advice to young oncologists just getting started in the field.
We traveled to Denver, Colorado, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured insights from University of Colorado and Rocky Mountain Cancer Centers faculty.
We traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma, which featured insights from the faculty from the Mount Sinai Hospital.
We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Genitourinary Cancers, which featured insights from the faculty from the Dana-Farber Cancer Institute.
We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the faculty from the Medical College of Wisconsin.
Stephen V. Liu, MD, of Medstar Georgetown University Medical Center, and Konstantinos Arnaoutakis, MD, of Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences, discuss the results of a Twitter poll regarding the use of single-agent immunotherapy versus combination chemotherapy and immunotherapy in a patient with nonsquamous non–small cell lung cancer and to shed light on the data that support each intended treatment choice.
We traveled to Lexington, Kentucky, for a State of the Science Summit™ on Neuroendocrine Tumors, which featured insights from the faculty from University of Kentucky Markey Cancer Center.
We traveled to Pasadena, California, for a State of the Science Summit™ on Breast Cancer, which featured insights from the faculty from City of Hope.
Patrick I. Borgen, MD, of Maimonides Medical Center, shares his live-by mottos as a breast cancer surgeon, a patient who defined his career, and what fuels his passion to fight breast cancer and remove opioid use after surgery.
We traveled to Dallas, Texas, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from Baylor Scott and White Health System faculty.
We traveled to Tampa, Florida, for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from the faculty from Moffitt Cancer Center and Mayo Clinic.
We traveled to Boston, Massachusetts, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the faculty from Dana-Farber Cancer Institute.
We traveled to Dallas, Texas, for a State of the Science Summit™ on Breast Cancer, where faculty relayed the prognostic value of genomic assays in breast cancer and the scope of established and ensuing treatment approaches for those with early-stage and advanced disease.
We recently traveled to Charlotte, North Carolina, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured expert insight on treatment approaches across metastatic colorectal cancer, locally advanced and metastatic pancreatic cancer, advanced hepatocellular carcinoma, neuroendocrine tumors, and advanced gastric cancer.
We traveled to New York City, New York, for a State of the Science Summit™ on Ovarian Cancer, where faculty shared their insight on the various surgical and medical treatment modalities in advanced ovarian cancer, as well as investigational interventions that may further define standards of care.
We traveled to Durham, North Caroline, for a State of the Science Summit™ on Gastrointestinal Malignancies, where faculty shared key updates from the 2019 Gastrointestinal Symposium.
We traveled to Chicago, Illinois, for a State of the Science Summit™ on Breast Cancer, where faculty provided a comprehensive look into present and potentially future standards of care in early-stage and advanced breast cancer subtypes.
We traveled to Washington, D.C., for a State of the Science Summit™ on Gastrointestinal Cancer, which focused on the clinically diverse and steadily expanding therapeutic armamentariums for patients with gastrointestinal malignancies.
We traveled to Kansas City, Missouri, for a State of the Science Summit™ on Hematologic Malignancies, which provided a comprehensive snapshot of the pivotal data that were presented at the 2018 ASH Annual Meeting.
Mario M. Leitao Jr, MD, FACOG, FACS, and Dmitriy Zamarin, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss two common clinical scenarios faced in practice, and the data to support their approaches.
We traveled to Houston, Texas, for a State of the Science Summit™ on Gastrointestinal Cancer, which focused on the rapidly evolving landscapes of colorectal cancer, gastric/GEJ cancer, pancreatic cancer, neuroendocrine tumors, and hepatocellular carcinoma.
We traveled to Nashville, Tennessee, for a State of the Science Summit™ on Breast Cancer, which focused on some of the practice-changing updates that have been occurring in the field.
